In SCCHN, combination therapy with the EGFR-antibody cetuximab yielded comparable results to chemoradiation regimen on retrospective comparisons [29,32] without increase of toxicity - except acneiforme skin reactions - and has therefore raised interest for this combination also in other histologies. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.